Amgen to sell fixed-rate notes in three parts via four bookrunners

By Mary-Katherine Stinson

Lexington, Ky., Aug. 15 – Amgen Inc. is marketing a three-part offering of fixed-rate senior notes (Baa1/A-/BBB+), according to a 424B3 filing with the Securities and Exchange Commission.

The notes are due 2029, 2033 and 2053.

The notes feature a make-whole call until two months prior to maturity for the 2029 notes, three months prior to maturity for the 2033 notes and six months prior to maturity for the 2053 notes and par calls after those dates.

The notes are redeemable at 101 should there be a change-of-control event.

BofA Securities Inc., Credit Suisse Securities (USA) LLC, Deutsche Bank Securities Inc. and Morgan Stanley & Co. LLC are the bookrunners.

Bank of New York Mellon Trust Co., NA is the trustee.

Latham & Watkins LLP will act as counsel for Amgen, and Shearman & Sterling LLP will be counsel for the bookrunners.

Proceeds will be used for general corporate purposes, including working capital, Amgen business investments, funding for acquisitions, including the proposed acquisition of ChemoCentryx, and upcoming debt maturities.

Amgen is a Thousand Oaks, Calif., manufacturer and marketer of human therapeutics based upon advances in cellular and molecular biology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.